Improvement of muscle strength in a mouse model for congenital myopathy treated with HDAC and DNA methyltransferase inhibitors

  1. Alexis Ruiz
  2. Sofia Benucci
  3. Urs Duthaler
  4. Christoph Bachmann
  5. Martina Franchini
  6. Faiza Noreen
  7. Laura Pietrangelo
  8. Feliciano Protasi
  9. Susan Treves
  10. Francesco Zorzato  Is a corresponding author
  1. Basel University Hospital, Switzerland
  2. University of Basel, Switzerland
  3. University G d' Annunzio of Chieti, Italy

Abstract

To date there are no therapies for patients with congenital myopathies, muscle disorders causing poor quality of life of affected individuals. In approximately 30% of the cases, patients with congenital myopathies carry either dominant or recessive mutations in the RYR1 gene; recessive RYR1 mutations are accompanied by reduction of RyR1 expression and content in skeletal muscles and are associated with fiber hypotrophy and muscle weakness. Importantly, muscles of patients with recessive RYR1 mutations exhibit increased content of class II histone de-acetylases and of DNA genomic methylation. We recently created a mouse model knocked-in for the p.Q1970fsX16+p.A4329D RyR1 mutations, which are isogenic to those carried by a severely affected child suffering from a recessive form of RyR1-related multi-mini core disease. The phenotype of the RyR1 mutant mice recapitulates many aspects of the clinical picture of patients carrying recessive RYR1 mutations. We treated the compound heterozygous mice with a combination of two drugs targeting DNA methylases and class II histone de-acetylases. Here we show that treatment of the mutant mice with drugs targeting epigenetic enzymes improves muscle strength, RyR1 protein content and muscle ultrastructure. This study provides proof of concept for the pharmacological treatment of patients with congenital myopathies linked to recessive RYR1 mutations.

Data availability

All data, code, and materials used in the analysis are available in some form to any researcher for purposes of reproducing or extending the analysis. There are no restrictions on materials, such as materials transfer agreements (MTAs). All data are available in the main text or the supplementary materials.

Article and author information

Author details

  1. Alexis Ruiz

    Department of Biomedicine, Basel University Hospital, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  2. Sofia Benucci

    Department of Biomedicine, Basel University Hospital, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  3. Urs Duthaler

    Department of Biomedicine, Basel University Hospital, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7811-3932
  4. Christoph Bachmann

    Department of Biomedicine, Basel University Hospital, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  5. Martina Franchini

    Department of Biomedicine, Basel University Hospital, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  6. Faiza Noreen

    Department of Biomedicine, University of Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  7. Laura Pietrangelo

    Department of Neuroscience, Imaging and Clinical Science, University G d' Annunzio of Chieti, Chieti, Italy
    Competing interests
    The authors declare that no competing interests exist.
  8. Feliciano Protasi

    Department of Neuroscience, Imaging and Clinical Science, University G d' Annunzio of Chieti, Chieti, Italy
    Competing interests
    The authors declare that no competing interests exist.
  9. Susan Treves

    Department of Biomedicine, Basel University Hospital, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0007-9631
  10. Francesco Zorzato

    Department of Biomedicine, Basel University Hospital, Basel, Switzerland
    For correspondence
    fzorzato@usb.ch
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8469-7065

Funding

Swiss National Science Foundation (SNF 310030_184765)

  • Susan Treves

Swiss Muscle Foundation (FRSMM)

  • Francesco Zorzato

NeRAB

  • Susan Treves

RYR1 Foundation

  • Francesco Zorzato

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations of the Basel Stadt Kantonal authorities. All animals were handled according to approved institutional animal care and use committee. The protocols were approved by the Kantonal Veterinary Authorities included in Licence permits numbers 1728 and 2950

Copyright

© 2022, Ruiz et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,547
    views
  • 216
    downloads
  • 9
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Alexis Ruiz
  2. Sofia Benucci
  3. Urs Duthaler
  4. Christoph Bachmann
  5. Martina Franchini
  6. Faiza Noreen
  7. Laura Pietrangelo
  8. Feliciano Protasi
  9. Susan Treves
  10. Francesco Zorzato
(2022)
Improvement of muscle strength in a mouse model for congenital myopathy treated with HDAC and DNA methyltransferase inhibitors
eLife 11:e73718.
https://doi.org/10.7554/eLife.73718

Share this article

https://doi.org/10.7554/eLife.73718

Further reading

    1. Chromosomes and Gene Expression
    2. Medicine
    Xianghong Xie, Mingyue Gao ... Xiaojun Liu
    Research Article

    LncRNAs are involved in modulating the individual risk and the severity of progression in metabolic dysfunction-associated fatty liver disease (MASLD), but their precise roles remain largely unknown. This study aimed to investigate the role of lncRNA Snhg3 in the development and progression of MASLD, along with the underlying mechanisms. The result showed that Snhg3 was significantly downregulated in the liver of high-fat diet-induced obesity (DIO) mice. Notably, palmitic acid promoted the expression of Snhg3 and overexpression of Snhg3 increased lipid accumulation in primary hepatocytes. Furthermore, hepatocyte-specific Snhg3 deficiency decreased body and liver weight, alleviated hepatic steatosis and promoted hepatic fatty acid metabolism in DIO mice, whereas overexpression induced the opposite effect. Mechanistically, Snhg3 promoted the expression, stability and nuclear localization of SND1 protein via interacting with SND1, thereby inducing K63-linked ubiquitination modification of SND1. Moreover, Snhg3 decreased the H3K27me3 level and induced SND1-mediated chromatin loose remodeling, thus reducing H3K27me3 enrichment at the Pparg promoter and enhancing PPARγ expression. The administration of PPARγ antagonist T0070907 improved Snhg3-aggravated hepatic steatosis. Our study revealed a new signaling pathway, Snhg3/SND1/H3K27me3/PPARγ, responsible for mice MASLD and indicates that lncRNA-mediated epigenetic modification has a crucial role in the pathology of MASLD.

    1. Evolutionary Biology
    2. Medicine
    Rion Brattig-Correia, Joana M Almeida ... Paulo Navarro-Costa
    Tools and Resources

    Male germ cells share a common origin across animal species, therefore they likely retain a conserved genetic program that defines their cellular identity. However, the unique evolutionary dynamics of male germ cells coupled with their widespread leaky transcription pose significant obstacles to the identification of the core spermatogenic program. Through network analysis of the spermatocyte transcriptome of vertebrate and invertebrate species, we describe the conserved evolutionary origin of metazoan male germ cells at the molecular level. We estimate the average functional requirement of a metazoan male germ cell to correspond to the expression of approximately 10,000 protein-coding genes, a third of which defines a genetic scaffold of deeply conserved genes that has been retained throughout evolution. Such scaffold contains a set of 79 functional associations between 104 gene expression regulators that represent a core component of the conserved genetic program of metazoan spermatogenesis. By genetically interfering with the acquisition and maintenance of male germ cell identity, we uncover 161 previously unknown spermatogenesis genes and three new potential genetic causes of human infertility. These findings emphasize the importance of evolutionary history on human reproductive disease and establish a cross-species analytical pipeline that can be repurposed to other cell types and pathologies.